Education
About Us
Working with TipRanks
Follow Us
Bruker Corp (BRKR)
NASDAQ:BRKR
BRKR Stock Chart & Stats
$33.35
-$0.59(-0.96%)
At close: 4:00 PM EST
$33.35
-$0.59(-0.96%)
Day’s Range― - ―
52-Week Range$28.53 - $56.22
Previous CloseN/A
Volume340.61K
Average Volume (3M)2.37M
Market Cap
$5.08B
Enterprise Value$6.82B
Total Cash (Recent Filing)$298.80M
Total Debt (Recent Filing)$2.04B
Price to Earnings (P/E)―
Beta1.20
Next Earnings
May 06, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend Yield0.42%
Share Statistics
EPS (TTM)0.59
Shares Outstanding152,219,250
10 Day Avg. Volume2,370,786
30 Day Avg. Volume2,370,625
Financial Highlights & Ratios
PEG Ratio6.94
Price to Book (P/B)2.91
Price to Sales (P/S)2.08
P/FCF Ratio165.16
Enterprise Value/Market Cap1.34
Enterprise Value/Revenue1.98
Enterprise Value/Gross Profit4.26
Enterprise Value/Ebitda22.95
Forecast
1Y Price Target
$45.00Price Target Upside34.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)2.12
Revenue Forecast (FY)$3.58B
Bulls Say, Bears Say
Bulls Say
Analyst Confidence And ValuationMultiple analysts maintain Buy ratings and cite a reasonable valuation after a modest preannouncement beat, which could attract investor interest if execution improves.
Pharmaceutical Customer DemandIncreased pharmaceutical customer spending is supporting demand for the company's instruments, improving visibility in a high-value end market.
Revenue DiversificationGrowth in lab automation and spatial biology provides new revenue streams outside the weak U.S. market, strengthening overall top-line resilience.
Bears Say
Guidance Execution RiskGuidance implies a steep profitability ramp that increases execution risk because planned cost actions may not boost results immediately.
Margin Shortfall And Profitability RiskReported gross margin shortfalls attributed to sales mix, tariffs, and currency effects raise doubts about near-term profitability and margin stability.
Revenue Seasonality And Demand UncertaintyUnusual revenue seasonality and choppy academic and government demand create uncertainty in revenue cadence and make it difficult to confirm steady progress.
Bruker News
BRKR FAQ
What was Bruker Corp’s price range in the past 12 months?
Bruker Corp lowest stock price was $28.53 and its highest was $56.22 in the past 12 months.
What is Bruker Corp’s market cap?
Bruker Corp’s market cap is $5.08B.
When is Bruker Corp’s upcoming earnings report date?
Bruker Corp’s upcoming earnings report date is May 06, 2026 which is in 45 days.
How were Bruker Corp’s earnings last quarter?
Bruker Corp released its earnings results on Feb 12, 2026. The company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by -$0.06.
Is Bruker Corp overvalued?
According to Wall Street analysts Bruker Corp’s price is currently Undervalued.
Does Bruker Corp pay dividends?
Bruker Corp pays a Quarterly dividend of $0.05 which represents an annual dividend yield of 0.42%. See more information on Bruker Corp dividends here
What is Bruker Corp’s EPS estimate?
Bruker Corp’s EPS estimate is 0.23.
How many shares outstanding does Bruker Corp have?
Bruker Corp has 152,219,250 shares outstanding.
What happened to Bruker Corp’s price movement after its last earnings report?
Bruker Corp reported an EPS of $0.59 in its last earnings report, missing expectations of $0.65. Following the earnings report the stock price went down -11.596%.
Which hedge fund is a major shareholder of Bruker Corp?
Currently, no hedge funds are holding shares in BRKR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bruker Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.00 (34.93% Upside)
$45.00 (34.93% Upside)
Blogger Sentiment
Neutral
BRKR Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.71%
12-Months-Change
Fundamentals
Return on Equity
-0.40%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Bruker Corp
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
BRKR Company Deck
BRKR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral: The company showed meaningful positives including a Q4 revenue beat, exceptional cash generation (Q4 operating cash flow of ~$230M, free cash flow $207M), strong order momentum (BSI book-to-bill >1.0, ~7 months backlog), large multiyear BEST orders (> $500M), and constructive FY2026 guidance with targeted margin expansion and raised cost-savings expectations. However, these positives are offset by material near-term challenges: persistent organic revenue declines (Q4 -5.1%, FY -3.7%), significant margin compression (Q4 non-GAAP operating margin down 240 bps), pressure from tariffs and FX, weak U.S. academic/government funding, and expected Q1 2026 organic decline. Taken together, the call presents a credible operational and financial recovery plan built on strong cash flow and order momentum, but also substantial short-term headwinds and execution/timing risks.View all BRKR earnings summariesBRKR Stock 12 Month Forecast
Average Price Target
$45.00
▲(34.93% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---